Recursion (RXRX) CEO Najat Khan logs 10b5-1 sale of 28,298 shares

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. CEO and President Najat Khan reported an open-market sale of 28,298 shares of Class A common stock on March 9, 2026 at a weighted average price of $3.3451 per share. The trades were executed at prices ranging from $3.32 to $3.405.

After this transaction, Khan directly holds 2,262,085 shares of Class A common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025, indicating the timing was set in advance rather than decided opportunistically.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khan Najat

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/09/2026		S(1)		28,298	D	$3.3451(2)	2,262,085	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025

2. This transaction was executed in multiple trades at prices ranging from $3.32 to $3.405. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RXRX CEO Najat Khan report?

Najat Khan reported an open-market sale of 28,298 shares of Recursion Pharmaceuticals Class A common stock. The transaction occurred on March 9, 2026 at a weighted average price of $3.3451 per share, according to the Form 4 insider trading report.

At what price did RXRX shares sell in Najat Khan’s latest Form 4?

The reported weighted average sale price was $3.3451 per RXRX share. The filing notes multiple trades executed within a price range from $3.32 to $3.405 per share, with full trade-by-trade details available upon request from the reporting person.

How many RXRX shares does Najat Khan hold after this sale?

Following the reported transaction, Najat Khan directly holds 2,262,085 shares of Recursion Pharmaceuticals Class A common stock. This remaining ownership figure comes directly from the Form 4 and helps show the scale of the sale relative to ongoing holdings.

Was the RXRX insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on September 22, 2025. Such pre-arranged plans schedule trades in advance, which can reduce the significance of the exact timing of the reported transaction.

Who is the insider involved in the latest RXRX Form 4 filing?

The insider is Najat Khan, CEO and President of Recursion Pharmaceuticals. The Form 4 identifies Khan as both an officer and director, and reports a direct ownership position in the company’s Class A common stock after completing the disclosed share sale.